Sphingosine kinases as druggable targets

Pyne, Susan and Adams, David R. and Pyne, Nigel J.; Gomez-Cambronero, Julian and Frohman, Michael A., eds. (2020) Sphingosine kinases as druggable targets. In: Lipid Signaling in Human Diseases. Springer Berlin Heidelberg, Cham, Switzerland, pp. 49-76. ISBN 978-3-030-33668-4

[thumbnail of Pyne-etal-Springer-Sphingosine-kinases-as-druggable] Text (Pyne-etal-Springer-Sphingosine-kinases-as-druggable)
Accepted Author Manuscript
Restricted to Repository staff only until 25 April 2022.

Download (1MB) | Request a copy from the Strathclyde author


    There is substantial evidence that the enzymes, sphingosine kinase 1 and 2, which catalyse the formation of the bioactive lipid, sphingosine 1-phosphate are involved in physiological and pathophysiological processes. In this chapter, we appraise the evidence that both enzymes are druggable and describe how isoform-specific inhibitors can be developed based on the plasticity of the sphingosine-binding site. This is contextualised with the effect of sphingosine kinase inhibitors in cancer, pulmonary hypertension, neurodegeneration, inflammation and sickling.

    ORCID iDs

    Pyne, Susan ORCID logoORCID: https://orcid.org/0000-0002-6608-9584, Adams, David R. and Pyne, Nigel J. ORCID logoORCID: https://orcid.org/0000-0002-5657-4578; Gomez-Cambronero, Julian and Frohman, Michael A.